Shanghai Zhangjiang (Group) Co., Ltd
Zhangjiang Group – The Heart of Shanghai’s Innovation Engine
Zhangjiang Science City is one of China’s leading innovation hubs, strategically located in Shanghai with a planned area of 220 km². As a global center for science and technology, it brings together world-class research institutions, industrial clusters, and corporate headquarters across key sectors such as biopharma, AI, medical devices, and advanced manufacturing.
With seamless connectivity—just 26 km from Pudong International Airport and 37 km from Hongqiao Transportation Hub—Zhangjiang offers unrivaled accessibility. Home to flagship projects like the AI Industrial Cluster, Fintech Dataport, and Cell & Gene Industrial Park, Zhangjiang Group fosters an ecosystem that enables startups, enterprises, and researchers to thrive.
Together, we are building a bridge between Swiss innovation and China’s dynamic market, leveraging Zhangjiang’s unique advantages to accelerate growth and global impact.
Innovation, Growth, and Global Reach and where Industry and Talent Converge
Zhangjiang Science City is one of China’s leading centers for innovation and industry. In 2024, it generated 1.32 trillion yuan in revenue, with its three pillar industries contributing over 470 billion yuan—half of Pudong’s industrial output. More than 10 enterprises exceed 10 billion yuan annually, underscoring the area’s global competitiveness.
Home to over 24,800 enterprises, including 1,930 high-tech companies and 105 listed firms, Zhangjiang has established itself as a premier sci-tech hub. Its international presence includes 181 foreign R&D centers and 70 multinational headquarters, while over 45 companies are listed on the SSE STAR Market. From pioneering IPOs in semiconductors and CROs to breakthroughs in CDMO and cell culture, Zhangjiang continues to set industry benchmarks and attract global innovators.
Driving this success is a workforce of nearly 500,000 employees, including more than 103,000 with a master’s degree or higher and 20,000 overseas returnees. With 80% youth talent, Zhangjiang combines experience with fresh innovation. Key industries are strengthened by 130,000+ software specialists, 56,000+ IC employees, and 94,000+ bio-pharmaceutical professionals, with advanced degree holders making up over a quarter of the talent base.
This deep pool of expertise and international perspective ensures Zhangjiang remains at the forefront of technological breakthroughs, economic growth, and global collaboration.
At the core of its ecosystem, Zhangjiang brings together 12 major national science and technology infrastructure projects and 15 leading universities and institutes. This includes facilities such as the Shanghai Synchrotron Radiation Facility, the National Protein Science Center, the Shanghai Supercomputer Center, and the Shanghai Soft X-ray Free Electron Laser Facility.
Alongside these, top academic institutions like ShanghaiTech University, Shanghai Jiao Tong University’s Zhangjiang Institute of Advanced Study, and the Shanghai Academy of Sciences drive cutting-edge research and innovation.
This concentration of large-scale infrastructure and high-level academic talent makes Zhangjiang one of the most important innovation clusters in China—and a critical hub for global scientific collaboration.
Bio-Pharmaceutical Innovation at Zhangjiang Science City
Zhangjiang Science City is at the forefront of global biopharmaceutical innovation, driving breakthroughs across advanced medical devices, AI-powered drug discovery, cell and gene therapy, and large-scale pharmaceutical manufacturing. With a strong concentration of leading enterprises, research institutions, and industrial platforms, Zhangjiang has become one of the world’s most dynamic life science clusters.
Pharma Valley
Known as China’s Pharma Valley, Zhangjiang combines research excellence with industrial scale. In 2023, the bio-pharmaceutical industry here generated 163 billion yuan in revenue, with 23% year-on-year growth and a 43% share of Pudong’s output.
7 of the world’s top 10 pharma companies are present in Zhangjiang.
The area accounts for 1/8 of China’s international patent applications (PCT) in biopharma.
Innovation achievements include 33 Class I drug applications, 40 IPOs, and cross-border licensing deals worth more than 300 billion yuan.
With 200 public technology platforms and over 100 CRO/CDMO providers, Zhangjiang offers unmatched resources for companies at every stage of development.
Cell and Gene Therapy
With over 100 enterprises covering the entire cell and gene therapy value chain, Zhangjiang is China’s strongest hub for next-generation therapies. From CAR-T and stem cell therapy to gene editing and nucleic acid drugs, Zhangjiang accounts for 45% of all clinical trials in Shanghai and 15% nationwide.
Breakthroughs include China’s first approved cell therapy drug, the first IPO of a gene therapy company on the STAR Market, and the world’s first clinical development of SMA gene therapy in China. Leading companies such as Novartis, BeiGene, Cansino, and numerous cutting-edge biotech startups drive this ecosystem forward.
AI Medicine
Artificial intelligence is transforming drug development, and Zhangjiang Science City is leading the way with 32 AI+ pharma companies, representing 80% of Shanghai’s total. AI-driven platforms accelerate every stage of the drug discovery pipeline, from target identification and protein modeling to dosage development and clinical trial optimization.
By integrating AI with traditional small molecule and biologics R&D, Zhangjiang startups and multinationals are cutting drug discovery timelines by up to 66% and reducing costs by 90% compared to traditional methods. Already, 19 AI+ pharma products have entered clinical trials, with several reaching Phase II.
Advanced Medical Devices
Zhangjiang hosts one of the world’s top medical device clusters, home to 6 of the global top 10 enterprises in the sector. In 2023 alone, 23 new devices were approved for marketing, with Shanghai capturing 55% of all approvals nationwide. The ecosystem spans implantable and interventional devices, surgical equipment, in-vitro diagnostics (IVD), and smart rehabilitation technologies.
A full industrial chain supports innovation—from incubators and CRO services to accelerators, clinical platforms, and production capabilities—ensuring rapid translation from research to market.
Integrated Circuits – Driving Shanghai’s Silicon Valley
Zhangjiang Science City has become the epicenter of China’s semiconductor industry, generating 189 billion yuan in IC revenue in 2023, accounting for 76% of Pudong’s share and hosting over 800 enterprises—one-third of Shanghai’s total.
It is home to 6 of the world’s top 10 chip design companies, 2 of the global top 6 foundries, and leading equipment manufacturers such as ASML, Lam, and Applied Materials. With 400+ chip design firms, 60+ materials and equipment companies, and 20+ packaging and testing enterprises, Zhangjiang covers the entire semiconductor value chain.
This unique concentration of global leaders and domestic innovators cements Zhangjiang’s reputation as China’s Silicon Valley for integrated circuits, driving technological breakthroughs and industrial growth.
Artificial Intelligence – Shaping the Future of Industry
Artificial intelligence is a cornerstone of Zhangjiang Science City’s innovation ecosystem. By combining cutting-edge research, enterprise clusters, and industrial applications, Zhangjiang has built a comprehensive AI value chain that extends from data and computing power to robotics, smart mobility, and AI-driven pharmaceuticals. This unique integration positions Zhangjiang as a global leader in translating AI into real-world impact.
Intelligence Valley
Zhangjiang Science City is at the forefront of China’s AI revolution, generating 77 billion yuan in AI revenue in 2023 and hosting 600+ enterprises across robotics, future mobility, pharmaceuticals, and data-driven services. With strong capabilities in intelligent computing, data technology, and 5G/6G networks, Zhangjiang provides the full-stack foundation for next-generation AI applications. Its ecosystem connects global leaders, startups, and research alliances, positioning it as a powerhouse for industrial AI innovation.
Humanoid Robots
Robotics is one of Zhangjiang’s flagship AI strengths, with over 80 enterprises active in the field. The cluster is driving breakthroughs in humanoid robots, from Fourier’s first mass-produced models and rehabilitation robots to Agibot’s AI-embedded innovations, Humanoid Robotics Company’s open-source co-creation platforms, and Kepler’s Pioneer series designed for general, outdoor, and high-risk environments. Supported by innovation platforms such as the ABB Robot Empowerment Center and the General-purpose Humanoid Robot Innovation Center, Zhangjiang is shaping the future of robotics and enabling large-scale AI integration.
Investment Ecosystem
Zhangjiang Science City has built a comprehensive investment and innovation ecosystem designed to empower talent, support enterprises, and connect global resources. From generous talent incentives and startup subsidies to incubators, accelerators, and low-rent spaces for youth enterprises, Zhangjiang ensures the right conditions for growth at every stage. Its network of global corporations, venture funds, and research institutions enables deep co-construction and international collaboration. With one of China’s densest incubation systems, thousands of companies have already scaled through Zhangjiang’s platforms. Complemented by a robust financing environment with 145+ direct investments, 56 funds, and ¥66 billion in private capital attracted, Zhangjiang stands as a closed-loop ecosystem where ideas, talent, capital, and innovation converge.
Investment, Financing & Academia
Zhangjiang serves as a platform for investment and innovation, with 145+ direct investment projects, 56 funds invested, and over ¥66 billion in private capital attracted. It manages dedicated funds such as Zhanke Herun and Zhanke Yaokun, while more than 1,300 firms issue bonds through Zhangjiang’s financing channels. This closed-loop ecosystem connects ideas, capital, incubation, and commercialization.
Innovation & Incubation
With 16 owned incubators, 30 open innovation centers with large enterprises, and an incubation area of over 250,000 m², Zhangjiang provides full-cycle incubation from makerspaces to commercialization bases. Over 3,870 companies have already been empowered through this ecosystem, making it one of the densest and most complete incubation networks in China.
Deep Co-Construction & Wide Connection
Zhangjiang collaborates with leading multinational corporations, investment institutions, and research organizations. Global giants like Johnson & Johnson, Roche, Siemens Healthineers, ABB, and PwC co-develop with Zhangjiang, while networks with Sequoia, SAP, Plug and Play China, and Hillhouse Capital ensure international reach and resource sharing.
Enterprise Support
Startups and enterprises benefit from incubators, rent subsidies, and kick-off grants of up to ¥1 million, alongside cash awards for competition winners. Innovation vouchers at municipal and Pudong levels provide additional funding, while low-rent incubation spaces for youth enterprises ensure affordable growth opportunities for the next generation of entrepreneurs.
Talent Support
Zhangjiang offers one of the most comprehensive talent support systems in China. Programs such as the Mingzhu Plan and Qiming Plan provide financial awards, housing support, and subsidies for entrepreneurs, innovative talent, and young professionals. Additional incentives include 15%+ income tax rebates for overseas high-level talent, dedicated residency policies, and transitional services like free accommodation and startup office space.
Insights
